Mustang Bio - MBIO STOCK NEWS

Mustang Bio (NASDAQ: MBIO) announced interim Phase 1/2 data on its CD20-targeted CAR T cell therapy, MB-106, for relapsed or refractory B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia. This data will be presented at the 2022 Tandem Meetings in Salt Lake City from February 2-6. CEO Manuel Litchman highlighted MB-106's promising efficacy and safety profile, aiming for further updates and a multicenter trial under Mustang's IND within the quarter. MB-106 is developed in collaboration with Fred Hutchinson Cancer Research Center.

Mustang Bio, Inc. (NASDAQ: MBIO), a clinical-stage biopharmaceutical company, announced participation in three virtual investor conferences in January 2022. The events include the 11th Annual LifeSci Partners Corporate Access Event (Jan 5-7), H.C. Wainwright Virtual BioConnect Conference (presentation available Jan 10), and B. Riley Securities’ Virtual Oncology Conference (fireside chat on Jan 28). Webcasts of the presentations will be accessible on Mustang's website for approximately 30 days post-event. Mustang aims to develop cell and gene therapies for various cancers and rare diseases.

Mustang Bio, Inc. (NASDAQ: MBIO) announced its inclusion in the NASDAQ Biotechnology Index® effective December 20, 2021. The NBI tracks biotechnology and pharmaceutical companies listed on NASDAQ and is re-ranked annually based on specific eligibility criteria, such as market capitalization and trading volume. This addition may enhance Mustang's visibility and attract greater investor interest, potentially impacting its stock performance positively. Mustang focuses on cell and gene therapies for various cancers and genetic diseases, advancing partnerships with leading medical institutions.

Mustang Bio, Inc. (NASDAQ: MBIO) announced promising results from its ongoing Phase 1/2 trial of MB-106, a CD20-targeted CAR T cell therapy for relapsed or refractory B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia. The trial demonstrated a significant overall response rate of 95% and a complete response rate of 65%, alongside a favorable safety profile. The data was presented at the 63rd ASH Annual Meeting. Mustang plans to conduct further trials under an IND approved by the FDA, with patient enrollment starting early next year.

Mustang Bio, a clinical-stage biopharmaceutical company focused on cell and gene therapies, will host a webinar on December 16, 2021, at 2:30 p.m. ET. The event will present interim results from the Phase 1/2 clinical trial of MB-106, a CD20-targeted CAR T cell therapy for B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia. Dr. Mazyar Shadman from Fred Hutch will lead the discussion, with a Q&A session to follow. Mustang's IND was accepted by the FDA to initiate this trial, aimed at evaluating the safety and efficacy of MB-106 in patients with relapsed or refractory conditions.

Mustang Bio, Inc. (NASDAQ: MBIO) reported Q3 financial results, showing a net loss of $17.0 million ($0.19/share), up from $13.0 million ($0.23/share) a year earlier. Cash and equivalents totaled $121.9 million, down from $130.9 million in Q2 2021. Significant advancements include promising data from MB-106 CD20-targeted CAR T therapy, achieving a 94% overall response rate. The company secured a $2 million grant from the NCI to support MB-106 and received PRIME designation for MB-107 from the EMA. Upcoming presentations and trials are anticipated to further validate their therapies.

Mustang Bio has signed an exclusive license agreement with Leiden University Medical Centre for a first-in-class ex vivo lentiviral gene therapy targeting RAG1 severe combined immunodeficiency (RAG1-SCID). This therapy is currently in a Phase 1/2 clinical trial in Europe, with the first patient enrolled. The RAG1-SCID program has received Orphan Drug Designation by the European Medicines Agency. Mustang's ongoing development of lentiviral gene therapies aims to address significant unmet needs in treating SCID, which affects nearly 60% of cases.

Mustang Bio (NASDAQ: MBIO) announced interim Phase 1/2 data on MB-106, a CD20-targeted CAR T cell therapy for relapsed or refractory B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia, to be presented at the 63rd ASH Annual Meeting on December 11-14, 2021. The treatment showed an overall response rate of 94% and a complete response rate of 62% among the 16 patients studied. No dose-limiting toxicities were recorded. Additionally, a webinar is scheduled for December 16, 2021, to discuss the updated results and future plans regarding the therapy.

Mustang Bio, Inc. (NASDAQ: MBIO) has received a $2 million grant from the National Cancer Institute to support a Phase 1 clinical trial of MB-106, a CAR T cell therapy targeting B-cell non-Hodgkin lymphomas and chronic lymphocytic leukemia. The trial aims to assess the treatment's safety and efficacy. Additionally, Mustang has obtained Federalwide Assurance approval, ensuring compliance with U.S. regulations for human research protection. The funding and approvals represent significant steps in advancing Mustang's therapeutic offerings in hematologic cancers.